News

  • Global HIV Vaccine Enterprise Holds Meeting of the Young and Early Career Investigators (YECI) Committee – July 6, 2009
    The minutes from the July 6 meeting of the YECI Committee can be found below.
    YECI Meeting Minutes – July 6, 2009

  • African AIDS Vaccine Program to Hold 5th International Forum on HIV Vaccine Development and Access in Kampala, Uganda – June 10, 2009
    The African AIDS Vaccine Program (AAVP) will convene various stakeholders to promote the development of and future access to HIV vaccines suitable for use in Africa during their 5th international forum in Kampala, Uganda on December 13-15, 2009. This forum will serve as a platform for participants to share experiences and identify strategies to further unite African communities and scientists in HIV vaccine research and development. For more information about the AAVP 5th international forum, please visit the link below.
    AAVP 5th international forum

  • Global HIV Vaccine Enterprise Holds Meeting of the Enterprise Coordinating Group to Prepare for the Release of HIV Vaccine Efficacy Trial Results (Coordinating Group) – June 3, 2009
    The Global HIV Vaccine Enterprise hosted the meeting of the Enterprise Coordinating Group to discuss preparations for the release of the Prime Boost HIV Vaccine Phase III Trial (Thai trial). A summary of the June 3rd meeting of the Enterprise Coordinating Group can be found below.
    Enterprise Coordinating Group Meeting Summary – June 3, 2009

  • Global HIV Vaccine Enterprise Holds Meeting of the Young and Early Career Investigators (YECI) Committee – May 19, 2009
    The minutes from the May 19 meeting of the YECI Committee can be found below.
    YECI Meeting Minutes - May 19, 2009

  • Global HIV Vaccine Enterprise Invites Participation in Upcoming HIV Vaccine Awareness Day Events – May 4, 2009
    The Global HIV Vaccine Enterprise announced a list of events to commemorate HIV Vaccine Awareness Day on May 18, 2009. For more information, please visit the link below.
    HIV Vaccine Awareness Day Events

  • Global HIV Vaccine Enterprise Council Members Recognized – May 4, 2009
    Dr. Rafi Ahmed, an ex-officio member of the Global HIV Vaccine Enterprise (the Enterprise) Council, and Dr. Seth Berkley, a member of the Enterprise Council, were recognized last week for their contributions to the field of HIV vaccine research and development. Dr. Ahmed, Director of the Emory Vaccine Center and Emory University, who also serves as Chair of the Enterprise Science Committee, was chosen by the National Academy of Sciences as a new member of the Academy. Dr. Berkley, President and CEO of the International AIDS Vaccine Initiative (IAVI), was named one of Time Magazine’s “100 Most Influential People in the World.” For more information, please visit the links below.
    Dr. Rafi Ahmed
    Dr. Seth Berkley

  • AVAC, TAG, and the Global HIV Vaccine Enterprise Host Roundtable Discussion on Community and Scientific Perspectives on the Future of AIDS Research – April 27, 2009
    AIDS Vaccine Advocacy Coalition (AVAC), Treatment Action Group (TAG), and the Global HIV Vaccine Enterprise will host a roundtable discussion, "Community and Scientific Perspectives on the Future of AIDS Research," at TAG’s headquarters in New York on May 18, 2009, HIV Vaccine Awareness Day. For more information, please view the event invitation below.
    Community and Scientific Perspectives on the Future of AIDS Research

  • Global HIV Vaccine Enterprise Holds Meeting of the Young and Early Career Investigators (YECI) Committee – April 23, 2009
    The minutes from the April 23rd meeting of the YECI Committee can be found below.
    YECI Meeting Minutes – April 23, 2009

  • Global HIV Vaccine Enterprise Solicits Applications for AIDS Vaccine 2011 Conference Local Host – April 21, 2009
    The annual AIDS Vaccine conference is an important opportunity for the world’s scientific community to gather and present the latest results of their research to peers. It is also a critical venue for scientists from the developing world, especially scientists at early stages in their careers, to present their work. Thus, the selection of a Local Host for the annual AIDS Vaccine conference is an important process. The Global HIV Vaccine Enterprise is soliciting applications from prospective Local Hosts outside North America. The conference rotates every year between North American and non-North American locations, and since the 2010 conference will take place in Atlanta, Georgia, U.S.A., the AIDS Vaccine conference in 2011 will take place outside North America. The Enterprise encourages qualified applicants involved in HIV vaccine research and development to complete the Local Host application form. The deadline for submission of applications is May 31, 2009.
    AIDS Vaccine Conference Local Host Application Form

  • Global HIV Vaccine Enterprise Holds Enterprise Council Meeting – April 14, 2009
    The Global HIV Vaccine Enterprise held its second Enterprise Council meeting in New York City on April 14, 2009. The Council held wide ranging discussions about current and planned Enterprise activities. The minutes from the April 14 meeting can be found below.
    Council Meeting Minutes – April 14, 2009

  • Global HIV Vaccine Enterprise Holds Meeting of the Board – April 13, 2009
    The Global HIV Vaccine Enterprise held a meeting of the Board in New York City on April 14, 2009 where many operational matters were discussed. The minutes from the April 13 meeting can be found below.
    Board Meeting Minutes – April 13, 2009

  • WHO and UNAIDS issue a Request for Proposal (RFP) for the Development of the African AIDS Vaccine Program (AAVP) Business Plan – April 6, 2009
    The WHO and UNAIDS issue a RFP to enter into a contractual agreement with a suitable contractor to carry out the development of the AAVP Business Plan for 2010 to 2015, including the development of a resource mobilization strategy. Also available are the Terms of Reference for the AAVP Transition Advisory Panel, which will provide overall guidance and advice to the AAVP Steering Committee and the AAVP Secretariat to facilitate a step-wise transition of AAVP into a fully functional African-led program based in Africa, aligned with the goals and objectives of all key stakeholders working on HIV vaccine R&D in Africa and consistent with the mission of the Global HIV Vaccine Enterprise.
    WHO/UNAIDS RFP for AAVP Business Plan
     UNAIDS RFP for AAVP Business Plan

  • Global HIV Vaccine Enterprise's Young and Early Career Investigators (YECI) Committee Holds Informal Meeting at Keystone Symposia – March 25, 2009
    The minutes from the informal YECI meeting can be found below.
    YECI Meeting Minutes - March 25, 2009

  • Global HIV Vaccine Enterprise Holds its Third Meeting of the Young and Early Career Investigators (YECI) Committee – March 20, 2009
    The minutes from the third meeting (in person) of the YECI Committee can be found below.
    YECI Meeting Minutes - March 20, 2009

  • Collaboration for AIDS Vaccine Discovery (CAVD) Report Now Available – March 17, 2009
    The Bill & Melinda Gates Foundation launched the Collaboration for AIDS Vaccine Discovery (CAVD) in July 2006 with grants to 16 institutions to create an international network of highly collaborative research consortia focused on developing an HIV vaccine. The CAVD is currently comprised of 95 collaborating institutions in 21 countries involving over 700 senior and junior investigators, project managers, administrators, legal representatives, and others. This is the first report on the cumulative progress of the CAVD since the first grants were awarded in July 2006, and is meant to provide CAVD members and the broader community of HIV vaccine stakeholders with an overview of the scientific and operational progress made over the last two and a half years.
    CAVD Report: 2006-2008 in Review

  • Spanish HIV BioBank Now Available – March 9, 2009
    The Spanish HIV BioBank was created with the objectives of processing, storing and providing distinct samples from HIV/AIDS patients, categorized according to strictly defined characteristics, free of charge to research projects. Strict compliance to ethical norms is always guaranteed. At the moment, the HIV BioBank possesses nearly 50,000 vials containing different prospective longitudinal study sample types. More than 1,700 of these samples are now used in 19 national and international research projects. For more information, please visit the link below.
    The Spanish HIV BioBank: A Model of Cooperative HIV Research

    Abstract: The Spanish HIV Biobank: a model of cooperative HIV Research

  • Global HIV Vaccine Enterprise Holds its Second Meeting of the Young and Early Career Investigators (YECI) Committee – February 19, 2009
    The minutes from the second meeting (by teleconference) of the YECI Committee can be found below.
    YECI Minutes - February 19, 2009

  • Global HIV Vaccine Enterprise Inaugurates its Young and Early Career Investigators (YECI) Committee - January 27, 2009
    The Global HIV Vaccine Enterprise (the Enterprise) YECI Committee held its inaugural meeting by teleconference on January 27, 2009. As part of the Enterprise’s New Minds, New Ideas Initiative, the YECI Committee serves as a source for suggestions and recommendations to the Enterprise on methods and approaches to attract and retain new scientific talent and to integrate innovative ideas and new technologies into HIV vaccine research and development. The initial charge of the YECI Committee is to contribute to the development of the Enterprise’s 2009 Scientific Strategic Plan by articulating the importance of YECIs as drivers of innovation and by proposing the structural changes required to engage and retain new scientific talent. The YECI Committee is comprised of scientists who are age 40 or younger or who are within 10 years of receiving their terminal degree or related clinical training. The minutes from this meeting can be found below.
    YECI Minutes - January 27, 2009

  • Global HIV Vaccine Enterprise Convened the Inaugural Meeting of the Enterprise Science Committee – January 21, 2009
    The inaugural meeting of the Global HIV Vaccine Enterprise (the Enterprise) Science Committee (SC) convened on January 21, 2009, at the Enterprise’s office in New York City, with the purpose of identifying critical issues in HIV vaccine research and development that must be addressed in the updated Enterprise Scientific Strategic Plan (SSP).
    Science Committee Meeting Minutes – January 21, 2009

  • WHO and UNAIDS Solicit Invitations for African Organizations to Host the African AIDS Vaccine Program (AAVP) in Africa – January 19, 2009
    The AAVP is a Network of African HIV Vaccine stakeholders committed to promoting HIV vaccine development for Africa through research, advocacy, partnership, and contribution to capacity strengthening and policy development. At present, the AAVP is housed under WHO's department of Immunization Vaccines and Biologicals. By the end of 2009, however, the AAVP will be an independent unit based in Africa. WHO and UNAIDS are requesting applications from eligible organizations in Africa who are willing to host the AAVP office.
    WHO / UNAIDS Request for Application

    AAVP Website

All Content ©2005 - 2009 Global HIV Vaccine Enterprise